GlaxoSmithKline plans to apply for emergency use authorisation for an experimental Covid-19 treatment after initial clinical trial results for their monoclonal antibodies showed an 85 per cent reduction in hospitalisation or death.https://www.ft.com/content/49bdda63-46d1-4ce5-b25c-030bd6f2e8f5?segmentid=acee4131-99c2-09d3-a635-873e61754ec6 …
-
-
This is misleading on one point. Monoclonal antibodies help those who are low on oxygen (compared to baseline), but those patients should be treated INPATIENT - - this summary is for outpatient use. Been doing this since December - very effective
End of conversation
New conversation -
-
Trying to get doctors To be proactive is damn near impossible
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
This is a therapeutic. It is given to high-risk individuals when they test positive in order to avoid hospitalization. These are not used on hospitalized patients. Thanks.
-
My nephew received them and they seemed to have been very beneficial to him.
End of conversation
New conversation -
-
-
Hold on now, a woke journalist just released an article that antibodies don’t work. Was that misinformation?
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
This Tweet is unavailable.
-
I've been giving this on outpatient basis on high risk patients since December. It has been very effective. In-office rapid-testing has been key to streamlining early treatment options. My optimism has never been better.
End of conversation
-
-
-
Say it isn't so..
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.